Changeflow GovPing Pharma & Drug Safety Novel Seven-Membered Ring-Fused Compounds - PRI...
Routine Notice Added Final

Novel Seven-Membered Ring-Fused Compounds - PRISM BioLab Co., Ltd.

Favicon for changeflow.com EPO Patent Bulletin - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The European Patent Office published patent application EP4508052A1 for PRISM BioLab Co., Ltd., covering novel seven-membered ring-fused compounds with potential therapeutic use for central nervous system disorders. The patent is designated across 31 European states including Germany, France, the United Kingdom, Italy, and Spain.

What changed

The EPO published patent application EP4508052A1 for PRISM BioLab Co., Ltd. covering novel seven-membered ring-fused compounds classified under C07D 487/04 and related pharmaceutical composition classifications. The compounds are indicated for neurological applications under A61P 25/00. The patent application was published April 1, 2026, designating 31 European contracting states.

Affected parties include pharmaceutical companies developing CNS-active compounds, as this patent may restrict freedom to operate in the seven-membered ring-fused compound space in Europe. Competitors should evaluate potential licensing requirements or invest in design-around research to develop non-infringing alternatives.

What to do next

  1. Monitor for updates on patent grant status
  2. Assess potential licensing or design-around requirements if developing similar compounds

Archived snapshot

Apr 9, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← EPO Patent Bulletin

NOVEL SEVEN-MEMBERED RING-FUSED COMPOUNDS

Publication EP4508052A1 Kind: A1 Apr 01, 2026

Applicants

PRISM BioLab Co., Ltd.

Inventors

KOUJI, Hiroyuki, ODAGAMI, Takenao, HIROSE, Yoichiro, TAKASHIMA, Hajime, HONDA, Eiji, OZAWA, Jun, YOSHIMORI, Atsushi

IPC Classifications

C07D 487/04 20060101AFI20260225BHEP A61K 31/551 20060101ALI20260225BHEP A61P 25/00 20060101ALI20260225BHEP C07D 495/14 20060101ALI20260225BHEP C07D 498/04 20060101ALI20260225BHEP C07D 498/10 20060101ALI20260225BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Get daily alerts for EPO Patent Bulletin - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from EPO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
EPO
Published
April 1st, 2026
Instrument
Notice
Legal weight
Binding
Stage
Final
Change scope
Minor
Document ID
EP4508052A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Pharmaceutical compound development Patent protection CNS drug research
Geographic scope
European Union EU

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Pharmaceuticals

Get alerts for this source

We'll email you when EPO Patent Bulletin - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.